Actively Recruiting
Observational Study of Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps Evaluating Real-World Clinical and Patient-Reported Outcomes
Led by AstraZeneca · Updated on 2026-10-23
200
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective, non-interventional study called PETRICHOR in Germany to observe adults with severe chronic rhinosinusitis with nasal polyps CRSwNP whose condition is not well controlled by systemic corticosteroids or surgery. The study focuses on patients newly starting treatment with subcutaneous tezepelumab as part of their routine medical care. Treatment decisions are made between patients and their doctors independently of the study. Participants receive tezepelumab following the European product guidelines during their usual clinical visits. No extra diagnostic or monitoring tests are performed beyond standard care. Data are collected at the beginning and throughout routine visits over a period of up to 104 weeks to understand real-world outcomes. Participants will continue their regular clinical visits during the study, where researchers gather information on symptoms using patient questionnaires like the SNOT-22 and other assessments related to nasal polyps, smell loss, and corticosteroid use. The main focus is the change in sino-nasal symptoms over time. Safety and treatment responses are tracked throughout routine care visits for up to two years.
CONDITIONS
Brief Title
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here